Streetbeat News

Revenues

HIW

Highwoods Properties (HIW) reported Q1 2024 FFO of $0.89 per share, meeting analyst estimates, and sales of $211.275M, exceeding expectations by 2.17%. However, this reflects a 9.18% decrease in earnings and a 0.69% decrease in sales from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:51 pm

V

Visa anticipates its fiscal year 2024 net revenue to grow in the low double-digit range, with earnings per share (EPS) expected to increase in the low-teens.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:28 pm

FVCB

FVCBankcorp (NASDAQ:FVCB) reported Q1 2024 earnings of $0.20 per share, meeting analyst estimates, but missed sales forecasts with $12.792M versus the expected $13.315M, marking an 8.72% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:25 pm

HA

Hawaiian Holdings projects its Q2 2024 Operating Revenue Per Available Seat Mile (RASM) to range between a decrease of 1.5% and an increase of 1.5%.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 8:04 pm

TNDM

Analyst ratings for Tandem Diabetes Care (NASDAQ:TNDM) show a mix of bullish and bearish perspectives with recent updates indicating an increase in the average 12-month price target to $34.0, up 26.87% from $26.80. The company, known for its insulin pumps, faces challenges with a revenue decline of -10.75% and a net margin of -15.25%, but stands out with a high ROE of -9.56%. Analysts from Stifel and Citigroup have raised their price targets, reflecting optimism in the company's market standing despite financial hurdles.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 7:01 pm

VERX

Vertex Inc (NASDAQ:VERX) received mixed analyst ratings over the past three months, with a shift towards more positive evaluations in the last 30 days. The average 12-month price target for VERX has been raised to $38.3, reflecting a 20.52% increase from the previous target. Analysts from firms including Citigroup, JMP Securities, B of A Securities, Goldman Sachs, BMO Capital, Needham, and Jefferies have updated their ratings and price targets, indicating a varied outlook on the company's performance. Vertex's financial metrics such as revenue growth, net margin, ROE, ROA, and debt management are highlighted, showcasing its market position and operational efficiency.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 7:00 pm

AFRM

Analyst evaluations of Affirm Holdings (NASDAQ:AFRM) show mixed sentiments with a recent upward trend in price targets, indicating an average target of $33.57, a 12.54% increase from the previous average. The company's financial overview reveals a notable revenue growth of 47.94% but challenges in profitability and debt management. Affirm Holdings operates a digital and mobile-first commerce platform, primarily in the U.S., facing below-industry benchmarks in market capitalization, net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 7:00 pm

IGT

Analyst ratings for Intl Game Tech (NYSE:IGT) show a mix of bullish and bearish perspectives with a recent average price target of $28.14, down from $30.17. The company's financial overview indicates a market capitalization challenge, a revenue growth of 3.39%, a net margin of -0.71%, an ROE of -0.55%, an impressive ROA of -0.08%, and a prudent debt management with a debt-to-equity ratio of 4.11.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 7:00 pm

BNTX

MRNA

PFE

Moderna Inc. is engaged in a patent trial in London against Pfizer Inc. and BioNTech SE over the use of mRNA technology in COVID-19 vaccines. Moderna alleges patent infringement, while Pfizer and BioNTech contest the claim. The trial could impact future mRNA technology use and financial compensations. Moderna seeks royalties from Pfizer and BioNTech's vaccine, Comirnaty, to offset declining sales of its own vaccine, Spikevax. The outcome may influence global intellectual property disputes and the development of mRNA-based treatments.

Portfolio Pulse from Vandana Singh

April 23, 2024 | 7:00 pm

CRK

Analyst evaluations of Comstock Resources (NYSE:CRK) over the last three months show a mix of opinions, with recent actions including both upgrades and downgrades. The average 12-month price target is now $9.5, a decrease from $9.86. The company faces challenges such as a significant revenue decline of -55.49% as of December 31, 2023, below-average net margin and ROE, and a high debt-to-equity ratio, indicating potential financial difficulties.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 7:00 pm